| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.096 | 0.02 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.02 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.02 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |